A mother with terminal illness is expressing her distress over losing friends prematurely due to the Government’s delay in approving a life-prolonging medication. Sophie Blake, a 53-year-old resident of Brighton, is facing incurable stage four breast cancer.
Sophie is heartbroken as she and her friends are being deprived of access to the innovative drug Enhertu. Within a short period, she has mourned the loss of two dear individuals who could have benefited from the drug, providing them with valuable additional time, including a mother with a young daughter.
Despite being accessible to women globally, Enhertu is currently inaccessible to women in England, Wales, and Northern Ireland who are living with HER2-low stage 4 secondary breast cancer. The drug, which offers the promise of extending life by six months, has not been approved for NHS use.
Expressing her grievances, Sophie stated, “I have witnessed the loss of many friends who urgently required this treatment.” She highlighted the recent passing of another advocate and close friend, a mother whose life could have been prolonged, granting her more time with her children. Sophie emphasized the dire consequences of the denial of this drug, pointing out that women are facing premature deaths as a result.
Sophie, a mother to an 18-year-old daughter, Maya Nicholls-Blake, was diagnosed in May 2022 with secondary breast cancer that had metastasized to multiple organs. Although she currently describes the cancer as dormant due to targeted medication, she remains apprehensive about its potential return, living with constant uncertainty.
Not having access to the drug has shattered hopes for Sophie and other affected women in the region, leaving them feeling undervalued compared to countries worldwide where the drug is available. The National Institute for Health and Care Excellence (NICE) rejected the drug in 2024, citing cost-effectiveness concerns.
Sophie expressed concerns that the rejection of advanced treatments could discourage pharmaceutical companies from seeking approvals, ultimately costing lives. She emphasized the urgency of the situation, highlighting the struggles faced by women with metastatic breast cancer in accessing necessary treatments and the impact of such decisions on their lives.
NICE’s inability to recommend Enhertu was attributed to the failure to reach a pricing agreement between the drug companies and NHS England, disappointing prospects for around 1000 affected women. The spokesperson emphasized the importance of fair pricing for ensuring timely access to vital medications, reiterating efforts to facilitate agreements for patient benefit.